Divi’s Laboratories’ profits boost in Q4FY16

Divi’s Laboratories has declared its Q4FY16 results on May 28. The company’s revenue has increased by 34.06 per cent to Rs 1095 crore in Q4FY16 as compared to same period in previous financial year. Its EBITDA too has risen by 26.28 per cent to Rs 398 crore in Q4FY16 on a yearly basis. Divi’s Laboratories’ EBITDA margin has contracted by 224 basis points to 36.33 per cent in Q4FY16 as compared to same period in previous fiscal year. The company’s PAT also has boosted by 40.76 per cent to Rs 322 crore in Q4FY16 on a yearly basis. Its PAT margin has expanded by 140 basis points to 29.42 per cent in Q4FY16 as compared to same period in previous financial year.

On the yearly front, Divi’s Laboratories’ top line has increased by 21.23 per cent to Rs 3776 crore in FY16 on a yearly basis. The company’s EBITDA also has risen by 21.33 per cent to Rs 1414 crore in Q4FY16 as compared to previous financial year. Its PAT has increased by 30.57 per cent to Rs 1112 crore in FY16 on a yearly basis. Divi’s Laboratories’ PAT margin has expanded by 210 basis points to 29.44 per cent in FY16 as compared to previous fiscal year.

The share price of Divi’s Laboratories’ has increased by 3.37 per cent on bourses in early trades; and is trading at Rs 1097.3 on an intraday basis.

Divi's Laboratories is in the manufacturing of generic active pharmaceutical ingredients (APIs), custom synthesis of active ingredients for companies, other specialty chemicals and nutraceuticals. The company is also involved in developing alternate, non-infringing processes for APIs, for the inventors to manage life cycle and generic drug manufacturers. It exports its products to European and the American countries. Divi’s Laboratories main manufacturing and research and development facilities are located in the state of Andhra Pradesh and Telangana, India.